Drug Trial Radar · NCT03275103
Dose-Escalation Study of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)
Last checked: Nov 19, 2026Latest source record: Feb 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
355
Actual
Start
Sep 19, 2017
Primary completion
Jan 7, 2026
Study completion Jan 7, 2026
Sponsor
- Lead sponsor
- Genentech, Inc.Roche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Sep 7, 2017
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase I, multicenter, open-label, dose-escalation study of cevostamab administered as a single agent by IV infusion to participants with relapsed or refractory multiple myeloma (R/R MM).
Conditions
- Multiple Myeloma
Interventions
CevostamabDrug
Cevostamab will be administered intravenously on a 21-day cycle, up to a total of 17 cycles.
TocilizumabDrug
Tocilizumab will be administered as premedication during Cycle 1.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants with Adverse Events (AEs)Time frame: Up to approximately 8 years
- Percentage of Participants With Dose-Limiting Toxicities (DLTs)Time frame: Up to approximately 8 years
- Arms E and J Only: Incidence and Severity of Cytokine-release Syndrome (CRS) Following Tocilizumab Premedication Followed by Treatment with CevostamabTime frame: Up to approximately 8 years
Locations
17 sites in 4 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama
Mayo Clinic Hospital - Arizona
Scottsdale, Arizona
City of Hope
Duarte, California
University of Colorado Denver
Aurora, Colorado
Dana Farber Cancer Institute
Boston, Massachusetts
Memorial Sloan Kettering
New York, New York
Mount Sinai Hospital
New York, New York
University of Pennsylvania
Philadelphia, Pennsylvania
Tennessee Oncology - Nashville
Nashville, Tennessee
The University of Texas MD Anderson Cancer Center
Houston, Texas
Peter MacCallum Cancer Center
East Melbourne, Victoria, Australia
Alfred Hospital
Melbourne, Victoria, Australia
University of Calgary Cumming School of Medicine
Calgary, Alberta, Canada
Princess Margaret Cancer Center
Toronto, Ontario, Canada
Jewish General Hospital
Montreal, Quebec, Canada
Hospital Clinico Universitario de Salamanca
Salamanca, Spain
Clinica Universidad de Navarra
Pamplona/iruña, Navarre, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.